ISRCTN90482012 https://doi.org/10.1186/ISRCTN90482012

Multimodal Augmented Reality for Operative Guidance in Interventional Neuroradiology

Submission date 14/08/2024	**Recruitment status** Recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [X] Record updated in last year
Registration date 03/09/2024	**Overall study status** Deferred	
Last Edited 16/05/2025	**Condition category** Other	

Plain English summary of protocol
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)
Principal Investigator

Contact name
Prof Kyriakos Lobotesis

ORCID ID
http://orcid.org/0000-0001-5093-9751

Contact details
Imperial College Healthcare NHS Trust
Charing Cross Hospital
Fulham Palace Road
London
United Kingdom
W6 8RF
-
k.lobotesis@nhs.net

Type(s)
Public, Scientific

Contact name
Dr Philip Pratt

Contact details
Medical iSight (UK) Ltd
9th Floor
107 Cheapside
London
United Kingdom
EC2V 6DN
-
pjp@medicalisight.com

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number
319189

ClinicalTrials.gov number
Nil known

Secondary identifying numbers
CPMS 54208

Study information

Scientific Title
Multimodal Augmented Reality for Operative Guidance in Interventional Neuroradiology

Acronym
MAROG-INR

Study objectives
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 21/02/2023, London - Dulwich Research Ethics Committee (Skipton House, 80 London Road, London, SE1 6LH, United Kingdom; +44 (0)207 104 8290; dulwich.rec@hra.nhs.uk), ref: 23/LO/0030

Study design
Single-centre interventional trial in patients undergoing interventional neuroradiology procedures

Primary study design

Interventional

Secondary study design

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet
Not available in web format

Health condition(s) or problem(s) studied
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type
Other

Primary outcome measure
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Secondary outcome measures
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Overall study start date
29/11/2022

Completion date
01/07/2026

Eligibility

Key inclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)

Patient

Age group
Adult

Sex
Both

Target number of participants
50

Key exclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment
01/09/2024

Date of final enrolment
01/04/2026

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
Charing Cross Hospital
Fulham Palace Road
London
United Kingdom
W6 8RF

Sponsor information

Organisation
Medical iSight (UK) Limited

Sponsor details
9th Floor
107 Cheapside
London

England
United Kingdom
EC2V 6DN
-
pjp@medicalisight.com

Sponsor type
Industry

Website
https://www.medicalisight.com/

Funder(s)

Funder type
Other

Funder Name
Self-funded

Results and Publications

Publication and dissemination plan
Full trial details will be published up to 30 months after the end of the trial. Results will be posted on or after the date of publication of full trial details.

Intention to publish date
21/02/2026

Individual participant data (IPD) sharing plan
The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

IPD sharing plan summary
Not expected to be made available